FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892989595> ?p ?o ?g. }

• W2892989595 endingPage "610" @default.
• W2892989595 startingPage "605" @default.
• W2892989595 abstract "Uveal melanoma (UM) is a rare form of melanoma without effective therapy. The biology of UM relies on several heat-shock protein 90 (Hsp90)-dependent molecules such as MET, MEK and AKT, making Hsp90 inhibition a rational approach. Patients with stage IV UM, measurable disease, and no previous chemotherapy were eligible. Patients received either ganetespib 200 mg weekly (cohort A) or 150 mg twice a week (cohort B). Primary endpoint response rate (RR) was assessed by RECIST. A total of 17 patients were accrued for this study, with seven in cohort A and 10 in cohort B. Liver metastases were present in 59%. Response outcomes included one partial response, four stable disease, 11 progressive disease, and one withdrawal for ORR: 5.9% and disease control rate of 29.4%. Progression-free survival was 1.6 months (cohort A) and 1.8 months (cohort B). Overall survival was 8.5 months (cohort A) and 4.9 months (cohort B). An overall 31% of adverse events were grade 3–4 and were mostly related to gastrointestinal toxicities. Early on-treatment (1 months) positron emission tomography showed reduction in metabolic activity in 24% of patients, suggesting a pharmacodynamic effect of Hsp90 inhibition. These early metabolic changes did not seem to be durable and/or clinically significant in relation to the 2-month response assessment. Hsp90 inhibition with ganetespib resulted in modest clinical benefit on two dosing schedules and was associated with significant, although manageable, gastrointestinal toxicity. Evidence of pharmacodynamic activity for Hsp90 inhibition was observed via positron emission tomography, which did not translate into clinical benefit, suggesting rapid development of resistance." @default.
• W2892989595 created "2018-10-05" @default.
• W2892989595 creator A5007052233 @default.
• W2892989595 creator A5008479799 @default.
• W2892989595 creator A5010837144 @default.
• W2892989595 creator A5023174631 @default.
• W2892989595 creator A5027029651 @default.
• W2892989595 creator A5037357027 @default.
• W2892989595 creator A5041066193 @default.
• W2892989595 creator A5049839632 @default.
• W2892989595 creator A5058855456 @default.
• W2892989595 creator A5058888805 @default.
• W2892989595 creator A5063337705 @default.
• W2892989595 creator A5071788399 @default.
• W2892989595 creator A5084967339 @default.
• W2892989595 date "2018-12-01" @default.
• W2892989595 modified "2023-09-24" @default.
• W2892989595 title "Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma" @default.
• W2892989595 cites W1508871122 @default.
• W2892989595 cites W1916004087 @default.
• W2892989595 cites W1979233636 @default.
• W2892989595 cites W1979775163 @default.
• W2892989595 cites W1980477426 @default.
• W2892989595 cites W2005576578 @default.
• W2892989595 cites W2012704875 @default.
• W2892989595 cites W2022531767 @default.
• W2892989595 cites W2026888844 @default.
• W2892989595 cites W2038434969 @default.
• W2892989595 cites W2053520756 @default.
• W2892989595 cites W2057802075 @default.
• W2892989595 cites W2073433320 @default.
• W2892989595 cites W2077517114 @default.
• W2892989595 cites W2078434983 @default.
• W2892989595 cites W2081962789 @default.
• W2892989595 cites W2094595413 @default.
• W2892989595 cites W2100541925 @default.
• W2892989595 cites W2139306838 @default.
• W2892989595 cites W2165636771 @default.
• W2892989595 cites W2175338710 @default.
• W2892989595 cites W2176548633 @default.
• W2892989595 cites W2189254184 @default.
• W2892989595 cites W2280440990 @default.
• W2892989595 cites W2286032795 @default.
• W2892989595 cites W2314557535 @default.
• W2892989595 cites W2522637881 @default.
• W2892989595 cites W2583872728 @default.
• W2892989595 cites W2604931745 @default.
• W2892989595 cites W2891644192 @default.
• W2892989595 cites W4293241248 @default.
• W2892989595 doi "https://doi.org/10.1097/cmr.0000000000000509" @default.
• W2892989595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30211813" @default.
• W2892989595 hasPublicationYear "2018" @default.
• W2892989595 type Work @default.
• W2892989595 sameAs 2892989595 @default.
• W2892989595 citedByCount "23" @default.
• W2892989595 countsByYear W28929895952019 @default.
• W2892989595 countsByYear W28929895952020 @default.
• W2892989595 countsByYear W28929895952021 @default.
• W2892989595 countsByYear W28929895952022 @default.
• W2892989595 countsByYear W28929895952023 @default.
• W2892989595 crossrefType "journal-article" @default.
• W2892989595 hasAuthorship W2892989595A5007052233 @default.
• W2892989595 hasAuthorship W2892989595A5008479799 @default.
• W2892989595 hasAuthorship W2892989595A5010837144 @default.
• W2892989595 hasAuthorship W2892989595A5023174631 @default.
• W2892989595 hasAuthorship W2892989595A5027029651 @default.
• W2892989595 hasAuthorship W2892989595A5037357027 @default.
• W2892989595 hasAuthorship W2892989595A5041066193 @default.
• W2892989595 hasAuthorship W2892989595A5049839632 @default.
• W2892989595 hasAuthorship W2892989595A5058855456 @default.
• W2892989595 hasAuthorship W2892989595A5058888805 @default.
• W2892989595 hasAuthorship W2892989595A5063337705 @default.
• W2892989595 hasAuthorship W2892989595A5071788399 @default.
• W2892989595 hasAuthorship W2892989595A5084967339 @default.
• W2892989595 hasConcept C104317684 @default.
• W2892989595 hasConcept C111113717 @default.
• W2892989595 hasConcept C112705442 @default.
• W2892989595 hasConcept C121608353 @default.
• W2892989595 hasConcept C126322002 @default.
• W2892989595 hasConcept C143998085 @default.
• W2892989595 hasConcept C197934379 @default.
• W2892989595 hasConcept C203092338 @default.
• W2892989595 hasConcept C205260736 @default.
• W2892989595 hasConcept C2775932338 @default.
• W2892989595 hasConcept C2776694085 @default.
• W2892989595 hasConcept C2777560012 @default.
• W2892989595 hasConcept C2777658100 @default.
• W2892989595 hasConcept C2778822529 @default.
• W2892989595 hasConcept C502942594 @default.
• W2892989595 hasConcept C535046627 @default.
• W2892989595 hasConcept C55493867 @default.
• W2892989595 hasConcept C71924100 @default.
• W2892989595 hasConcept C72563966 @default.
• W2892989595 hasConcept C86803240 @default.
• W2892989595 hasConcept C90924648 @default.
• W2892989595 hasConceptScore W2892989595C104317684 @default.
• W2892989595 hasConceptScore W2892989595C111113717 @default.
• W2892989595 hasConceptScore W2892989595C112705442 @default.

• next